Amotiv Limited (AOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amotiv Limited (AOV) has a cash flow conversion efficiency ratio of 0.090x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$68.96 Million ≈ $49.88 Million USD) by net assets (CA$767.27 Million ≈ $555.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Amotiv Limited defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Amotiv Limited - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Amotiv Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Amotiv Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amotiv Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gan Yuan Foods Co Ltd
SHE:002991
|
0.067x |
|
Shanghai National Center of Testing and Inspection for Electric Cable and Wire Co. Ltd.
SHE:301289
|
-0.003x |
|
Wesure Global Tech Ltd
TA:WESR
|
-0.005x |
|
Benakat Petroleum Energy
JK:BIPI
|
0.004x |
|
Sunny Loan Top Co Ltd
SHG:600830
|
0.007x |
|
Shenzhen Properties & Resources Development Group Ltd
SHE:000011
|
-0.709x |
|
Shandong Binzhou Bohai Piston Co Ltd
SHG:600960
|
-0.045x |
|
Sparebanken Møre
OL:MORG
|
0.026x |
Annual Cash Flow Conversion Efficiency for Amotiv Limited (2014–2025)
The table below shows the annual cash flow conversion efficiency of Amotiv Limited from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Amotiv Limited market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$767.27 Million ≈ $555.03 Million |
CA$68.96 Million ≈ $49.88 Million |
0.090x | +96.96% |
| 2024-12-31 | CA$795.11 Million ≈ $575.17 Million |
CA$36.28 Million ≈ $26.24 Million |
0.046x | -5.18% |
| 2023-12-31 | CA$746.87 Million ≈ $540.28 Million |
CA$35.94 Million ≈ $26.00 Million |
0.048x | -1.83% |
| 2022-12-31 | CA$825.86 Million ≈ $597.41 Million |
CA$40.48 Million ≈ $29.28 Million |
0.049x | -7.50% |
| 2021-12-31 | CA$842.02 Million ≈ $609.10 Million |
CA$44.62 Million ≈ $32.28 Million |
0.053x | +484.77% |
| 2020-12-31 | CA$886.24 Million ≈ $641.09 Million |
CA$-12.21 Million ≈ $-8.83 Million |
-0.014x | -374.21% |
| 2019-12-31 | CA$915.11 Million ≈ $661.97 Million |
CA$4.60 Million ≈ $3.32 Million |
0.005x | +190.14% |
| 2018-12-31 | CA$1.03 Billion ≈ $745.11 Million |
CA$-5.74 Million ≈ $-4.15 Million |
-0.006x | -123.54% |
| 2017-12-31 | CA$991.21 Million ≈ $717.02 Million |
CA$23.46 Million ≈ $16.97 Million |
0.024x | +57.32% |
| 2016-12-31 | CA$979.72 Million ≈ $708.71 Million |
CA$14.74 Million ≈ $10.66 Million |
0.015x | +26.49% |
| 2015-12-31 | CA$642.06 Million ≈ $464.46 Million |
CA$7.64 Million ≈ $5.52 Million |
0.012x | +609.11% |
| 2014-12-31 | CA$478.99 Million ≈ $346.49 Million |
CA$803.34K ≈ $581.13K |
0.002x | -- |
About Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more